ArticleOncotarget2016
Transcriptomic profiling of urine extracellular vesicles reveals alterations of CDH3 in prostate cancer.
Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 1 synthesis or guideline pooled it, 67 citations in OpenAlex.
- Urinary extracellular vesicles: A position paper by the Urine Task Force of the International Society for Extracellular Vesicles.Journal of extracellular vesicles · 2021Guideline
- Extracellular vesicles in prostate cancer: current understanding and future perspectives.Journal of the National Cancer Center · 2026Review
- CDH3 in human tumors: tumor biology and potential therapeutic target.Frontiers in pharmacology · 2026Review
- Role of exosomes in cancer: from diagnosis to therapy.Discover oncology · 2025Review
- Defining Biological Variability, Analytical Precision and Quantitative Biophysiochemical Characterization of Human Urinary Extracellular Vesicles.Journal of extracellular vesicles · 2025Article
- Secreted spermidine synthase reveals a paracrine role for PGC1α-induced growth suppression in prostate cancer.Cell death & disease · 2025Article
- Applications of Urinary Extracellular Vesicles in the Diagnosis and Active Surveillance of Prostate Cancer.Cancers · 2024Review
- The Current Progress and Future Options of Multiple Therapy and Potential Biomarkers for Muscle-Invasive Bladder Cancer.Biomedicines · 2023Review
- CHRDL1, NEFH, TAGLN and SYNM as novel diagnostic biomarkers of benign prostatic hyperplasia and prostate cancer.Cancer biomarkers : section A of Disease markers · 2023Article
- Extracellular vesicles as a source of prostate cancer biomarkers in liquid biopsies: a decade of research.British journal of cancer · 2022Review
- Personalized medicine: From diagnostic to adaptive.Biomedical journal · 2022Review
- Molecular and pathological subtypes related to prostate cancer disparities and disease outcomes in African American and European American patients.Frontiers in oncology · 2022Article
- Emerging role of extracellular vesicles in kidney diseases.Frontiers in pharmacology · 2022Review
- Label-free optical redox ratio from urinary extracellular vesicles as a screening biomarker for bladder cancer.American journal of cancer research · 2022Article
- Extracellular Vesicle Proteome in Prostate Cancer: A Comparative Analysis of Mass Spectrometry Studies.International journal of molecular sciences · 2021Review
- The biology, function, and applications of exosomes in cancer.Acta pharmaceutica Sinica. B · 2021Review
- Screening and identification of potential biomarkers and therapeutic drugs in melanoma via integrated bioinformatics analysis.Investigational new drugs · 2021Article
- Using single-vesicle technologies to unravel the heterogeneity of extracellular vesicles.Nature protocols · 2021Review
- Extracellular vesicles in prostate cancer: a narrative review.Translational andrology and urology · 2021Review
- A novel similarity score based on gene ranks to reveal genetic relationships among diseases.PeerJ · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Extracellular vesicles (EV) are emerging structures with promising properties for intercellular communication. In addition, the characterization of EV in biofluids is an attractive source of non-invasive diagnostic, prognostic and predictive biomarkers. Here we show that urinary EV (uEV) from prostate cancer (PCa) patients exhibit genuine and differential physical and biological properties compared to benign prostate hyperplasia (BPH). Importantly, transcriptomics characterization of uEVs led us to define the decreased abundance of Cadherin 3, type 1 (CDH3) transcript in uEV from PCa patients. Tissue and cell line analysis strongly suggested that the status of CDH3 in uEVs is a distal reflection of changes in the expression of this cadherin in the prostate tumor. CDH3 was negatively regulated at the genomic, transcriptional, and epigenetic level in PCa. Our results reveal that uEVs could represent a non-invasive tool to inform about the molecular alterations in PCa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.